Novel pyridone EP₄ agonists featuring allylic alcohol ω-chains

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Prostaglandin E2 receptor 4 (EP4) plays a crucial role in various physiological and pathological processes.
• Developing selective EP4 agonists is a significant therapeutic goal for managing inflammatory and other conditions.

Purpose of the Study:

• To discover and characterize novel selective prostaglandin E2 receptor 4 (EP4) agonists.
• To explore structure-activity relationships (SAR) for optimizing EP4 agonist potency and selectivity.

Main Methods:

• Synthesis of novel compounds featuring a pyridone core and an allylic alcohol ω-chain.
• Evaluation of receptor binding and functional assays to determine selectivity across EP receptor subtypes (EP1, EP2, EP3, EP4).
• Systematic modification of structural elements, including the α-chain, to assess impact on potency.

Main Results:

• Discovery of novel EP4 agonists with a pyridone core and allylic alcohol ω-chain.
• Demonstrated high selectivity of the novel agonists for EP4 over EP1, EP2, and EP3 receptors.
• Identified that analogs with a 4-carboxylic acid phenethyl α-chain exhibited enhanced potency compared to those with an n-heptanoic acid chain.
• Elucidated key structure-activity relationships guiding further optimization.

Conclusions:

• Successfully identified novel, selective EP4 agonists with potential therapeutic applications.
• The findings provide a foundation for the development of EP4-targeted therapeutics.
• Key SAR insights will facilitate the design of more potent and selective EP4 agonists.